R
Romulus Capital Management, LLC
+ HoldingHIND
+0.00%
3M Return
$1.600
-0.029 (-1.84%)At close
Loading chart…
- High
- 1.660
- Open
- 1.660
- VWAP
- 1.61
- Volume
- 19.77K
- Mkt Cap
- —
- Low
- 1.570
- Amount
- 31.83K
- EV/EBITDA, TTM
- -0.56
Vyome Holdings, Inc. is a clinical-stage healthcare holding company. The Company is focused on leveraging its clinical-stage assets to transform the lives of patients with immuno-inflammatory conditions. Its clinical program VT1953 Gel is focused on cancer patients who are suffering from malignant fungating wounds (MFW). Its preclinical development program, VT1908, is a non-steroidal eye drop, which is focused on Uveitis. Its other business unit is focused on offering artificial intelligence (AI)-driven healthcare solutions across mental health and inflammation care, digital therapeutics and psychoneuroimmunology.
AI analysis of Vyome Holdings Inc (HIND)
HoldCurrently, Vyome Holdings Inc (HIND) is not a good buy due to its extremely low RSI of 17.286, indicating oversold conditions, and a significant year-to-date change of -54.93%. While the analyst target suggests potential upside, the current financial instability and negative earnings reports raise concerns.
Valuation Metrics
The current forward P/E ratio for Vyome Holdings Inc (HIND) is 0.00, compared to its 5-year average forward P/E of -8.15.
Whales holding HIND
Events Timeline
News
5.009-14NewsfilterVyome Holdings Appoints New CFO Jerry Leonard
9.505-29seekingalphaVyome Holdings Reports Q1 Revenue of $31.59M
- 7.505-28Newsfilter
Vyome Partners with Impetis for JAK Inhibitors, Targeting $57B Market
- 9.503-26seekingalpha
Vyome Holdings Reports FY 2025 Financial Results
- 8.502-18Newsfilter
Vyome Publishes Preclinical Data for VT-1908
HIND FAQ — answered by Alphio AI
Vyome Holdings, Inc. is a clinical-stage healthcare holding company. The Company is focused on leveraging its clinical-stage assets to transform the lives of patients with immuno-inflammatory conditions. Its clinical program VT1953 Gel is focused on cancer patients who are suffering from malignant fungating wounds (MFW). Its preclinical development program, VT1908, is a non-steroidal eye drop, which is focused on Uveitis. Its other business unit is focused on offering artificial intelligence (AI)-driven healthcare solutions across mental health and inflammation care, digital therapeutics and psychoneuroimmunology. It operates in the Healthcare sector.
Currently, Vyome Holdings Inc (HIND) is not a good buy due to its extremely low RSI of 17.286, indicating oversold conditions, and a significant year-to-date change of -54.93%. While the analyst target suggests potential upside, the current financial instability and negative earnings reports raise concerns.
Community
More ↗No posts yet
Sign up or log in to join the discussionRelated articles
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
- Santa Claus Rally and the Year-End Stock Market: Investor Guide for Late 2026Santa Claus rally explained: 7-day window stats since 1950, Nov–Dec seasonality, post-midterm 2026 setup, and a risk-managed year-end investing playbook.
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.